Physician profile
Tedra E Estis
NPI 1548612468
$12,626.92
in general payments reported to CMS, 2019-2025
6 companies · $114 in 2025
The $114 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $216 · 2022: $177 · 2023: $7,694 · 2024: $4,426 · 2025: $114.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,125 · Travel and Lodging: $2,023 · Food and Beverage: $1,086.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,125.00 |
| Travel and Lodging | $2,023.22 |
| Food and Beverage | $1,085.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $6,915.52 | 2021-2025 | Lybalvi, Aristada |
| Abbvie INC. | $5,108.55 | 2021-2023 | |
| E.R. Squibb & Sons, L.L.C. | $179.32 | 2024-2025 | Cobenfy |
| Otsuka America Pharmaceutical, INC. | $169.60 | 2021-2023 | Rexulti, Abilify Maintena |
| Janssen Pharmaceuticals, INC | $152.79 | 2021-2023 | Invega Sustenna |
| Neurocrine Biosciences, INC. | $101.14 | 2023 | Ingrezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tedra Estis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.